Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Atea Pharmaceuticals, Inc. (AVIR : NSDQ)
 
 • Company Description   
Atea Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. Atea Pharmaceuticals Inc. is based in BOSTON.

Number of Employees: 59

 
 • Price / Volume Information   
Yesterday's Closing Price: $7.51 Daily Weekly Monthly
20 Day Moving Average: 650,468 shares
Shares Outstanding: 83.26 (millions)
Market Capitalization: $625.27 (millions)
Beta: -0.58
52 Week High: $46.91
52 Week Low: $5.31
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 21.13% 32.72%
12 Week 26.86% 37.65%
Year To Date -16.00% -0.10%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
125 SUMMER STREET
-
BOSTON,MA 02110
USA
ph: 857-284-8891
fax: -
investors@ateapharma.com http://www.ateapharma.com
 
 • General Corporate Information   
Officers
Jean-Pierre Sommadossi - President; Chief Executive Officer and Chairman
Andrea Corcoran - Chief Financial Officer and Executive Vice Preside
Wayne Foster - Executive Vice President; Chief Accounting Officer
Franklin Berger - Director
Jerome Adams - Director

Peer Information
Atea Pharmaceuticals, Inc. (CORR.)
Atea Pharmaceuticals, Inc. (RSPI)
Atea Pharmaceuticals, Inc. (CGXP)
Atea Pharmaceuticals, Inc. (BGEN)
Atea Pharmaceuticals, Inc. (GTBP)
Atea Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 04683R106
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 83.26
Most Recent Split Date: (:1)
Beta: -0.58
Market Capitalization: $625.27 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.56 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.31 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: 14.73
PEG Ratio: -
Price Ratios
Price/Book: 0.92
Price/Cash Flow: 5.15
Price / Sales: 1.78
EPS Growth
vs. Year Ago Period: -250.00%
vs. Previous Quarter: -138.06%
Sales Growth
vs. Year Ago Period: 295.16%
vs. Previous Quarter: 485.72%
ROE
03/31/22 - 7.54
12/31/21 - 19.58
09/30/21 - 4.27
ROA
03/31/22 - 6.04
12/31/21 - 14.56
09/30/21 - 2.89
Current Ratio
03/31/22 - 24.93
12/31/21 - 13.58
09/30/21 - 3.22
Quick Ratio
03/31/22 - 24.93
12/31/21 - 13.58
09/30/21 - 3.22
Operating Margin
03/31/22 - -
12/31/21 - 34.49
09/30/21 - 11.89
Net Margin
03/31/22 - -
12/31/21 - 34.49
09/30/21 - 11.89
Pre-Tax Margin
03/31/22 - 23.06
12/31/21 - 39.44
09/30/21 - 18.29
Book Value
03/31/22 - 8.17
12/31/21 - 8.54
09/30/21 - 7.02
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©